Recent regulatory shifts have critical implications for how biosimilar developers generate and prioritise information. Read ICON’s latest article in PharmTech Magazine, to learn what these changes mean for data collect...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Proving long-term value in advanced therapies: Digital technologies can measure durability of effect
This article by Marie McCarthy and Bob Swann discusses how robust assessments based on digital data are a means of reducing the uncertainty that HTA bodies and payers face in making decisions around advanced therapy medicinal products.
-
Global collaboration: Irish company ICON on scaling up COVID-19 vaccine trials
An interview in which Steve Cutler gives a short overview of ICON and describes the company’s role in the Pfizer/BioNTech trial, explaining how the FDA played a critical role in expediting regulatory approvals.
-
A selection of thought leadership materials from ICON experts on Decentralised & Hybrid Clinical Trials
-
The effect of Covid-19 solutions on the clinical trials process
Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership.
-
-
International Women's Day: An interview with Marelise Epstein
Marelise Epstein is interviewed for International Women's Day and provides a glimpse into her work day and what inspires her.
-
How COVID-19 has changed pharmacovigilance
Dr Andrew Garrett contributes to this article in Pharmafocus: How COVID-19 has changed pharmacovigilance. The article explores how drug safety can be ensured while numerous vaccines and treatments come to market in record time to deal with COVID-19.
-
How scientists John Climax and Dr Ronan Lambe created an icon
An article reporting on the growth of ICON as it acquires PRA Health Sciences.
-
-
ICON CEO on PRA deal: Groundwork laid for faster trials (Radio)
A radio intervew with ICON CEO Steve Cutler about the ICON-PRA Health Sciences deal, which is the largest healthcare transaction this year at $12 billion.
